Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 303Unknown 77Terminated 49Active not recruiting 43Recruiting 32Withdrawn 19Suspended 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 2Lymphoid 2Other solid neoplasm 1Genitourinary 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1HTLV-I Infections 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 8Vincristine 7Prednisone 6Specimen Handling 5Rituximab 5Doxorubicin 5zanubrutinib 3prednylidene 3deltacortene 3Magnetic Resonance Spectroscopy 3tazemetostat 2fludarabine phosphate 2fludarabine 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Biopsy 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1ponatinib 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Etoposide × Lymphoid × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04803201 2026-05-06

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡